Financial resultsFiled on BSE ·
Bajaj Healthcare Ltd announces unaudited Q2 & H1 FY27 financial results and key updates
Bajaj Healthcare · Pharmaceuticals & Biotechnology
What the filing says
- Approved unaudited standalone financial results for Q2 and H1 ended Sept 30, 2026, with limited review by Walker Chandiok & Co LLP
- Reported H1 FY27 total income of ₹341.53 crore; profit after tax from continuing operations ₹28.27 crore; loss from discontinued operations ₹0.48 crore
- Completed sale of certain units; acquired Genrx Pharmaceuticals Private Ltd, pending NCLT approval received Oct 13, 2026 to consolidate as subsidiary
Original filing
Results-Financial Results For September 30, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Bajaj Healthcare
- Acquisition / mergerBajaj Healthcare Limited announces unaudited Q2 and H1 FY2026-27 financial results
- Acquisition / mergerBajaj Healthcare reports Q2 & H1 FY27 results with revenue and profit growth
- Acquisition / mergerBajaj Healthcare Limited received NCLT approval for acquisition of Genrx Pharmaceuticals
Other financial results filings this fortnight
- Financial resultsUrban CompanyUrban Company Limited approves Q2 FY27 financial results and fundraise plan
- Financial resultsPersistent Systems LtdPersistent Systems Ltd announces Q2 & H1 FY27 audited financial results and approvals
- Financial resultsIndian BankIndian Bank approves unaudited Q2 and H1 FY 2026-27 financial results and fund raising plan
- Financial resultsEimco Elecon(I)Eimco Elecon (India) Ltd Q2 & H1 FY27 results and CFO resignation announced
- Financial resultsArmee InfotechArMee Infotech Limited schedules Board Meeting for financial results and fund raising
- Financial resultsICICI AMCICICI Prudential AMC reports Q2 FY27 results and approves interim dividend
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.